These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9763217)

  • 1. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases.
    Platt FM; Butters TD
    Biochem Pharmacol; 1998 Aug; 56(4):421-30. PubMed ID: 9763217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
    Jeyakumar M; Butters TD; Dwek RA; Platt FM
    Neuropathol Appl Neurobiol; 2002 Oct; 28(5):343-57. PubMed ID: 12366816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
    Platt FM; Jeyakumar M; Andersson U; Priestman DA; Dwek RA; Butters TD; Cox TM; Lachmann RH; Hollak C; Aerts JM; Van Weely S; Hrebícek M; Moyses C; Gow I; Elstein D; Zimran A
    J Inherit Metab Dis; 2001 Apr; 24(2):275-90. PubMed ID: 11405346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases.
    Platt FM; Butters TD
    Expert Rev Mol Med; 2000 Feb; 2(1):1-17. PubMed ID: 14585134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substrate reduction therapy for glycosphingolipid storage disorders.
    Lachmann RH; Platt FM
    Expert Opin Investig Drugs; 2001 Mar; 10(3):455-66. PubMed ID: 11227045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.
    Platt FM; Neises GR; Reinkensmeier G; Townsend MJ; Perry VH; Proia RL; Winchester B; Dwek RA; Butters TD
    Science; 1997 Apr; 276(5311):428-31. PubMed ID: 9103204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
    Butters TD; Dwek RA; Platt FM
    Adv Exp Med Biol; 2003; 535():219-26. PubMed ID: 14714898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease.
    Sawkar AR; D'Haeze W; Kelly JW
    Cell Mol Life Sci; 2006 May; 63(10):1179-92. PubMed ID: 16568247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lyso-glycosphingolipids: presence and consequences.
    van Eijk M; Ferraz MJ; Boot RG; Aerts JMFG
    Essays Biochem; 2020 Sep; 64(3):565-578. PubMed ID: 32808655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
    Jeyakumar M; Butters TD; Cortina-Borja M; Hunnam V; Proia RL; Perry VH; Dwek RA; Platt FM
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6388-93. PubMed ID: 10339597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of Glycosphingolipids and Their Role in the Pathophysiology of Lysosomal Storage Disorders.
    Ryckman AE; Brockhausen I; Walia JS
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy of lysosomal storage disorders.
    Salvetti A; Heard JM; Danos O
    Br Med Bull; 1995 Jan; 51(1):106-22. PubMed ID: 7767637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemistry of glycosphingolipid degradation.
    Sandhoff K; Kolter T
    Clin Chim Acta; 1997 Oct; 266(1):51-61. PubMed ID: 9435988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substrate reduction therapy of glycosphingolipid storage disorders.
    Aerts JM; Hollak CE; Boot RG; Groener JE; Maas M
    J Inherit Metab Dis; 2006; 29(2-3):449-56. PubMed ID: 16763917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in treating glycosphingolipid storage diseases.
    Platt FM; Jeyakumar M; Andersson U; Dwek RA; Butters TD
    Adv Exp Med Biol; 2005; 564():117-26. PubMed ID: 16400817
    [No Abstract]   [Full Text] [Related]  

  • 17. New prospects for the treatment of lysosomal storage diseases.
    Schiffmann R; Brady RO
    Drugs; 2002; 62(5):733-42. PubMed ID: 11929328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glycosphingolipidoses-from disease to basic principles of metabolism.
    Schuette CG; Doering T; Kolter T; Sandhoff K
    Biol Chem; 1999; 380(7-8):759-66. PubMed ID: 10494825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease.
    Vu M; Li R; Baskfield A; Lu B; Farkhondeh A; Gorshkov K; Motabar O; Beers J; Chen G; Zou J; Espejo-Mojica AJ; Rodríguez-López A; Alméciga-Díaz CJ; Barrera LA; Jiang X; Ory DS; Marugan JJ; Zheng W
    Orphanet J Rare Dis; 2018 Sep; 13(1):152. PubMed ID: 30220252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into glycosphingolipid functions--storage, lipid rafts, and translocators.
    Sillence DJ
    Int Rev Cytol; 2007; 262():151-89. PubMed ID: 17631188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.